Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial

International Journal of Cancer

Volumn 139, Issue 11, 2016, Pages 2456-2466

  Isidean, Sandra D ^a   Mayrand, Marie Hélène ^a,b   Ramanakumar, Agnihotram V ^a   Gilbert, Laura ^c   Reid, Stephanie L ^c   Rodrigues, Isabel ^b   Ferenczy, Alex ^d   Ratnam, Sam ^e   Coutlée, François ^a,f   Franco, Eduardo L ^a,g   Abruz, L ^g   Abruzzese, L ^g   Bellegarde, K ^g   Bernardin, M ^g   Duarte, E ^g   Ferdinand, F ^g   Kelsal, G ^g   Mayrand, M H ^g   Raufin, M ^g   Piche S ^g   Poirier, J ^g   Rodrigues, A ^g   Rousseau, N ^g   Schwartz, C ^g   Slavtcheva, N ^g   Tunistky, E ^g   Batstone, A ^g   Condon, G ^g   Fitzpatrick, A ^g   Francis, P ^g   Halfyard, B ^g   Head, C ^g   Leonard, C ^g   Mason, D ^g   McGrath, J ^g   Moulton, V ^g   Oates, E ^g   Shea, W ^g   Arsenault, M Y ^g   Asselin, G ^g   Authier, L ^g   Bagga, S ^g   Bastien, P ^g   Bazinet, L ^g   Beaudoin, F ^g   Beaulieu, P ^g   Bedard M J ^g   Belinski, S ^g   Belisle S ^g   Benoit, J ^g   Bernard, M ^g   Bianki, S ^g   Biron, L ^g   Bissonnette, F ^g   Bou Habib, R ^g   Bourque, J ^g   Bradbury, B ^g   Champagne, M ^g   Charles, Y ^g   Choquette, P ^g   Couture, J N ^g   Dao, H Q ^g   Desjardins, C ^g   Desjardins, J ^g   Desrosiers, L ^g   DiTommaso, S ^g   Dontigny, L ^g   Doyle, M ^g   Dube J ^g   Dupuis, M J ^g   Durocher, F ^g   Engel, F ^g   Fafard, B ^g   Ferenczy, A ^g   Fortier, G ^g   Fortin, A ^g   Fortin, C ^g   Francoeur, D ^g   Frechette, D ^g   Fugere P ^g   Gagne G ^g   Gascon, S ^g   Gaudreau, M J ^g   Gaudron, D ^g   Gemayel, K ^g   Gilbert, L ^g   Gilbert, S ^g   Gill, J ^g   Girard, I ^g   Gobeil, A ^g   Gobl, A ^g   Granger, L ^g   Grou, E ^g   Grou, F ^g   Guertin, G ^g   Guimond, J ^g   Hemmings, R ^g   Ifergan, N ^g   Johnson, C ^g   Johnson, L ^g   Ketchian, L ^g   Korcaz, Y ^g   Lafortune, C ^g   Lalande, J ^g   Lanctot, J F ^g   Landry, D ^g   Landry, M ^g   Langevin, D ^g   Langlois, I ^g   Lanmy Monnot, L ^g   Lapensee L ^g   Larouche, L ^g   Laurin, D ^g   Lavigne, M C ^g   Lavoie, Y ^g   Leduc, M ^g   Leger, F ^g   Leroux, N ^g   Luskey, G ^g   Mansour, N ^g   Marceau, J ^g   Masse, A ^g   Mayrand, I ^g   McLauchlin, L R ^g   Menard, S ^g   Mercer, C ^g   Messier, M ^g   Michon, B ^g   Nadeau, M ^g   Nguyen, M ^g   Ouellet, S ^g   Paquin, C ^g   Pare R ^g   Peloquin, S ^g   Piche Y ^g   Pichet, R ^g   Rivard, C ^g   Rodrigues, I ^g   Roman, S ^g   Rusimovic, L ^g   Sanche, G ^g   Souliere D ^g   Sproule, D ^g   Steben, M ^g   Still, S ^g   Theriault, D ^g   Tondreau, G ^g   Tremblay, D ^g   MinhDungVo, T ^g   Whitehead, V M ^g   Yaffe, M ^g   DiZazzo, A ^g   Ziegler, C ^g   Bannister, E ^g   Callahan, E ^g   Collingwood, J ^g   Crocker, P ^g   Dawson, L ^g   Drover, A ^g   Dunne, J ^g   Fifield, F ^g   Fitzgerald, J ^g   Fontaine, D ^g   Grandy, B ^g   Greene, M ^g   Halley, K ^g   Hatcher, L ^g   Hickey, J ^g   Horwood, P ^g   Janes, J ^g   Jardine, F ^g   Kieley, L ^g   King, S ^g   Kirby, C ^g   Kum, N ^g   Mate, E ^g   McGrath, S ^g   McManamon, C ^g   Misik, K ^g   O'Dea, M ^g   O'Shea, P ^g   Peddle, C ^g   Penton, M ^g   Pike, C ^g   Power, P ^g   Rogers, L ^g   Saunders, K ^g   Sullivan, T ^g   Verge, J ^g   Wadden, P ^g   Watson, M ^g   Young, M ^g   Coutlee F ^g   Ratnam, S ^g   more..

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Newfoundland and Labrador Public Health Laboratory   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g Centre Hospitalier de l'Université de Montréal ^*

Author keywords

cervical cancer; cytology; genotyping; human papillomavirus; screening

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENETIC RISK; GENOTYPE; GOLD STANDARD; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; PAPANICOLAOU TEST; PATIENT SAFETY; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

EID: 84988027330     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30385     Document Type: Article

References (40)

1. IARC, Human papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer, Lycon, France, 1995.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–9.
3. IARC. Cancer Fact Sheet. GLOBOCAN, Lycon, France, 2012.
4. Isidean SD, Coutlee F, Franco EL. Cobas 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. Expert Rev Mol Diagn 2014;14:5–16.
5. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30:F88–99.
6. Castle PE, de Sanjose S, Qiao YL, et al. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 2012;30Suppl5:F117–22.
7. Canadian Task Force on Preventive Health C, Pollock S, Dunfield L, et al. Recommendations on screening for cervical cancer. CMAJ 2013;185:35–45.
8. Murphy J, Kennedy EB, Dunn S, et al. Cervical screening: a guideline for clinical practice in Ontario. J Obstet Gynaecol Can 2012;34:453–8.
9. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516–42.
10. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072–9.
11. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478–88.
12. Wright TC, Jr., Stoler MH, Sharma A, et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 2011;136:578–86.
13. Chen HC, Schiffman M, Lin CY, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011;103:1387–96.
14. Mayrand MH, Duarte-Franco E, Coutlee F, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006;119:615–23.
15. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579–88.
16. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–9.
17. Coutlee F, Rouleau D, Petignat P, et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol 2006;44:1998–2006.
18. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012;136:1266–97.
19. Kaplan EL, Meier P. Nonparametric-Estimation from Incomplete Observations. J Am Stat Assoc 1958;53:457–81.
20. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–70.
21. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol 2009;10:321–2.
22. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26Suppl10:K1–16.
23. von Karsa L, Arbyn M, De Vuyst H, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res 2015;1:22–31.
24. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663–72.
25. Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 2014;106.
26. Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015;136:189–97.
27. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754
28. Elfstrom KM, Smelov V, Johansson AL, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ 2014;348:g130
29. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249–57.
30. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32.
31. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78–88.
32. C Kitchener H, Canfell K, Gilham C, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess 2014;18:1–196.
33. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46–52.
34. Hoyer H, Scheungraber C, Kuehne-Heid R, et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int J Cancer 2005;116:136–43.
35. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007;370:890–907.
36. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Women's Health 2012;21:1031–7.
37. Zhu C, Bassig BA, Zhang Y, et al. A birth cohort analysis of the incidence of adenocarcinoma of the uterine cervix in the USA. Eur J Cancer Prev 2015;24:240–4.
38. Wheeler CM, Hunt WC, Schiffman M, et al. Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study G. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis 2006;194:1291–9.
39. Castle PE, Glass AG, Rush BB, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol 2012;30:3044–50.
40. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study G. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500–5.